Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes(Exelixis (United States)), Alison Joly(Exelixis (United States))
Cited by 1,316
Related Papers
Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling
|Biochemical Pharmacology|2004|38